COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits
- Conditions
- Sars-CoV2
- Registration Number
- NCT04412473
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
Current management of VID-19 consists of oxygen support without specific treatment. Hospitalization may suddenly require delayed resuscitation. This evolution corresponds to an atypical acute respiratory distress syndrome (ARDS), the mechanism of which is poorly understood and difficult to predict. The general pathophysiology of ARDS, the vascular tropism of SARS-Cov2, the description of coagulopathy and numerous pulmonary artery thromboses in resuscitation and the encouraging investigation of antithrombotics in general ARDS
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
- Major Subject (≥18 years)
- Subject hospitalised in HUS or GHRMSA for COVID-19
- The diagnosis COVID-19 confirmed by smear or evoked by CT scan or chest X-ray without a differential diagnosis retained in the medical record
- Subjects who, after being informed, do not wish to have their data reused for the purposes of this research
Exclusion Criteria
- Subject who expressed opposition to participating in the study
- Subject under guardianship or trusteeship
- Subject under safeguard of justice
- Patient hospitalized in a geriatric service or in a ward not labeled COVID (surgery, oncology,...) or in a short-term hospitalization unit without transfer to another service.
- Serious patient on admission to the emergency room and recused from resuscitation.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Analysis of Respiratory Distress and Antithrombolytic Therapy in Patients with covid19 1 month
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Service Médecine Intensive et Réanimation
🇫🇷Strasbourg, France